- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapy in Biliary Tract Cancers
Authors
Keywords
Biliary tract cancer, Targeted therapy, EGFR, VEGF, Trial
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 16, Issue 10, Pages -
Publisher
Springer Nature
Online
2015-08-12
DOI
10.1007/s11864-015-0366-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
- (2015) J. S. Chen et al. ANNALS OF ONCOLOGY
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
- (2015) Ming-Huang Chen et al. Oncotarget
- Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
- (2015) Andrea Lunardi et al. Oncotarget
- A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
- (2014) A. Santoro et al. ANNALS OF ONCOLOGY
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
- (2014) R. Buzzoni et al. ANNALS OF ONCOLOGY
- Sequential Occurrence of Preneoplastic Lesions and Accumulation of Loss of Heterozygosity in Patients With Gallbladder Stones Suggest Causal Association With Gallbladder Cancer
- (2014) Kajal Jain et al. ANNALS OF SURGERY
- Notch signaling: switching an oncogene to a tumor suppressor
- (2014) C. Lobry et al. BLOOD
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
- (2014) A F Hezel et al. BRITISH JOURNAL OF CANCER
- Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
- (2014) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Mutation profiling in gallbladder cancer in Indian population
- (2014) Niraj Kumari et al. Indian Journal of Pathology and Microbiology
- Molecular diagnosis of intrahepatic cholangiocarcinoma
- (2014) Hiroaki Haga et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Outcomes in biliary malignancy
- (2014) Bas Groot Koerkamp et al. JOURNAL OF SURGICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
- (2014) Maolan Li et al. NATURE GENETICS
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
- (2013) D. P. S. Sohal et al. ANNALS OF ONCOLOGY
- Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
- (2013) David Lebwohl et al. Annals of the New York Academy of Sciences
- Efficacy of gemcitabine plus platinum agents for biliary tract cancers
- (2013) Rui Yang et al. ANTI-CANCER DRUGS
- Potential Therapeutic Targets for the Primary Gallbladder Carcinoma: Estrogen Receptors
- (2013) Ling-Qiang Zhang et al. Asian Pacific Journal of Cancer Prevention
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
- (2013) Susanne Krege et al. BJU INTERNATIONAL
- Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
- (2013) Vikram Deshpande et al. BMC CANCER
- A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
- (2013) J K Lee et al. BRITISH JOURNAL OF CANCER
- Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study
- (2013) G. Rubovszky et al. EUROPEAN JOURNAL OF CANCER
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site
- (2013) Felipe A. Castro et al. INTERNATIONAL JOURNAL OF CANCER
- Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan
- (2013) Yu-Ting Chang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Obesity and cholangiocarcinoma
- (2013) Mansour A Parsi WORLD JOURNAL OF GASTROENTEROLOGY
- Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
- (2012) L. H. Jensen et al. ANNALS OF ONCOLOGY
- Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma
- (2012) Dario Ribero ARCHIVES OF SURGERY
- Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers
- (2012) Sarwa Darwish Murad et al. GASTROENTEROLOGY
- EGFR Expression in Gallbladder Carcinoma in North America
- (2012) Matthew Kaufman et al. International Journal of Medical Sciences
- Hepatitis B virus infection increases the risk of cholangiocarcinoma: A meta-analysis and systematic review
- (2012) Min Li et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The double-edged sword of Notch signaling in cancer
- (2012) Andrew P. South et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Influence of Surgical Margins on Outcome in Patients With Intrahepatic Cholangiocarcinoma
- (2011) Olivier Farges et al. ANNALS OF SURGERY
- A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
- (2011) Jun Ho Yi et al. EUROPEAN JOURNAL OF CANCER
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- (2011) Anthony B. El-Khoueiry et al. INVESTIGATIONAL NEW DRUGS
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
- (2011) Koichi Shimizu et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma
- (2011) Hyun Ah Yoon WORLD JOURNAL OF GASTROENTEROLOGY
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
- (2010) Ymera Pignochino et al. BMC CANCER
- Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer
- (2010) Allyson J. Ocean et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- National Trends in the Management and Survival of Surgically Managed Gallbladder Adenocarcinoma Over 15 years: A Population-Based Analysis
- (2010) Skye C. Mayo et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
- (2009) J W Valle et al. BRITISH JOURNAL OF CANCER
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib
- (2009) Gillian M. Keating et al. DRUGS
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Sorafenib and Sunitinib
- (2009) A. Kim et al. ONCOLOGIST
- Epidemiology of biliary tract cancers: an update
- (2008) G. Randi et al. ANNALS OF ONCOLOGY
- The antecedents of biliary cancer: a primary care case–control study in the United Kingdom
- (2008) M J Grainge et al. BRITISH JOURNAL OF CANCER
- Hedgehog: functions and mechanisms
- (2008) M. Varjosalo et al. GENES & DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started